Does Medicare Cover Memory Care?

The financial planning conversation for an Alzheimer’s diagnosis is the conversation no one wants to have at the moment they have to have it. The immediate concerns — driving safety, medication management, supervision — pull all the attention. Meanwhile, the long arc of dementia care costs is sliding toward the family largely uncovered by the program everyone assumes covers seniors.

If you’re an adult child of someone newly diagnosed with mild cognitive impairment or early-stage Alzheimer’s, the financial planning window is now. Medicare will cover the medical care — and that medical care matters more in 2026 than it did even three years ago because of the new monoclonal antibody treatments and the GUIDE care management model. But the housing and personal care portion of dementia, which is most of the multi-year cost, is yours to plan for.

Why memory care is excluded — same reason as assisted living

Memory care is a specialized form of assisted living for residents with dementia. It costs more than standard assisted living because of higher staffing ratios, secured perimeters, specialized staff training, and adapted physical environments. The 2026 national median for memory care is $7,000 to $9,000 per month, though it varies dramatically by region — coastal metros run higher, rural areas sometimes lower.

From Medicare’s perspective, the categorization is the same as standard assisted living: this is custodial care. The Medicare program statutorily excludes custodial care, defined as care that helps with activities of daily living and routine activities that don’t require professional medical training. The fact that memory care is more intensive, more expensive, and more medically necessary for the resident doesn’t change the categorization.

This is the gap that creates most family financial stress in dementia care.

What Medicare actually covers for someone with dementia

The list of covered services is meaningful, even if it doesn’t include the housing bill:

Medical visits and diagnostics

• Neurology visits, primary care, specialist evaluations: Part B at 20% coinsurance
• Cognitive assessments and the annual Medicare wellness visit (which now includes a cognitive screening): covered without coinsurance
• Diagnostic imaging (PET scans for amyloid biomarkers, MRIs to rule out other causes): Part B at 20% coinsurance
• Lab work (including the newer plasma biomarker tests becoming available): Part B at 20% coinsurance

Medications

• Aricept (donepezil), Exelon (rivastigmine), Razadyne (galantamine), Namenda (memantine): Part D, typically Tier 1 or 2 with low copays
• Newer monoclonal antibody treatments (Leqembi, Kisunla): Part B because they’re infused in clinic, with the standard 20% coinsurance

Care management

• The GUIDE model, if your provider participates: comprehensive care coordination, caregiver support, 24/7 navigator access, up to $2,500/year in respite — no patient cost-sharing

Home and community services

• Home health (skilled nursing, PT, OT) for homebound patients with skilled care needs: $0 coinsurance for covered home health visits
• Hospice care when the patient meets terminal criteria: $0 coinsurance for hospice services

Hospital and short-term skilled care

• Hospital admissions: full Part A coverage with applicable deductibles and coinsurance
• Skilled nursing facility for short-term rehab after qualifying hospital stay (e.g., recovery after a fall and hip surgery): up to 100 days under Part A

Durable medical equipment

• Hospital beds, wheelchairs, walkers, commodes, oxygen: Part B at 20%

Mental health

• Behavioral health visits, psychiatric medication management: Part B at 20%

What this list demonstrates: Medicare is far from absent. It covers the entire medical care plan for a person with dementia. It just doesn’t cover where they live or who helps them with daily life.

The new monoclonal antibody treatments and what they cost

This deserves its own section because it’s the biggest change in dementia care in the past two years.

Leqembi (lecanemab) and Kisunla (donanemab) are infused monoclonal antibody therapies for patients with early-stage Alzheimer’s disease confirmed by amyloid biomarkers. Both received full FDA approval (Leqembi in July 2023, Kisunla in July 2024) and CMS approved Medicare coverage of both, contingent on:

• Confirmed amyloid pathology (PET scan or cerebrospinal fluid biomarker)
• Mild cognitive impairment or mild dementia stage of Alzheimer’s
• Patient enrollment in a CMS-required data collection registry
• Treatment by a participating clinician

Coverage details:

• Drug administered in clinic → covered under Part B
• 20% Part B coinsurance applies (Medigap covers this)
• The drug itself runs $26,500/year list price for Leqembi; without Medigap, the patient share is around $5,300/year
• Pre-treatment imaging and post-treatment MRI surveillance for ARIA (amyloid-related imaging abnormalities) are also covered

For Original Medicare patients with a Medigap policy, the practical out-of-pocket cost of Leqembi is essentially zero. For Medicare Advantage patients, the cost depends on the plan’s specialty drug copay structure and prior authorization requirements.

These drugs don’t reverse Alzheimer’s — they slow progression by roughly 25–35% over 18 months in clinical trials. Whether they’re worth the time, infusion burden, and ARIA risk is a clinical decision your neurologist will help guide. From a coverage standpoint, the door is open.

The GUIDE model — underused but valuable

The Guiding an Improved Dementia Experience (GUIDE) model started in July 2024 as a CMS demonstration program. Participating practices receive a per-member-per-month payment from Medicare to provide comprehensive dementia care, including:

• A designated care navigator
• 24/7 access to dementia care expertise via phone
• Comprehensive care plans
• Caregiver education and support
• Coordination across providers
• Up to $2,500/year of respite care services

Hundreds of practices participate as of 2026. There is no patient cost-sharing — Medicare pays the practice directly. The benefit goes to traditional Medicare beneficiaries (not Medicare Advantage) with confirmed dementia.

The respite component is particularly valuable. Family caregivers can use the $2,500/year for in-home respite care, adult day services, or short-term residential respite — meaningful relief that’s hard to access otherwise.

Ask your parent’s primary care physician or neurologist whether they’re a GUIDE participant. If they are, enrollment is usually a simple consent form. If they’re not, ask if there’s a participating practice in your area you could transfer care to.

How families pay for memory care

The funding sources mirror assisted living, though the higher cost intensifies the math:

Personal resources: Income (Social Security, pension), liquid assets, retirement accounts. Most families exhaust personal liquid assets within 2–4 years at memory care prices.

Home equity: Sale of the family home is the most common single source. Reverse mortgage is occasionally used but problematic if the resident wants to retain the option to return home.

Long-term care insurance: If purchased before diagnosis. Most policies have a benefit trigger of cognitive impairment requiring substantial supervision — well-defined and generally non-controversial.

VA Aid and Attendance: For wartime veterans and surviving spouses meeting financial criteria. Up to roughly $2,300/month for a veteran in 2026.

Medicaid HCBS waivers: Once private resources are depleted. State-specific. Generally requires income and asset eligibility plus the level of care that would otherwise require nursing home placement. Many memory care facilities are Medicaid-participating; many premium ones are not.

Hospice: Once the person qualifies for hospice (terminal prognosis of 6 months or less), Medicare’s hospice benefit overlays the medical care without changing the room and board. This typically reduces medical costs to near zero in the final months.

A practical framework many families use: pay privately while assets last (often 2–4 years), apply for Medicaid as private resources approach the eligibility threshold, work with an elder law attorney on Medicaid spend-down planning, and use VA benefits if applicable. The math is harsh, but the path is well-traveled.

Bottom line

Medicare covers the medical care of a person with dementia thoroughly — including increasingly capable disease-modifying treatments and new care management programs — but does not cover the residency cost of memory care. For most families, dementia care planning becomes a multi-source funding exercise: personal assets, long-term care insurance if available, VA benefits if eligible, eventual Medicaid eligibility, and hospice in the late stages. Start the financial planning conversation early. The hardest moment to figure all this out is during a crisis admission; the easiest is months ahead, while everyone can still participate.